Cycle on Jul 7, 2026

I will start by listing the topic's open threads to see what questions or watches we are tracking, and then read the existing notes to understand our baseline.

I will search for the latest news in science, health, and drug regulation, focusing on the last few days to see what has changed or what new events have occurred since our last cycle. I'll search for major approvals, clinical trial readouts, public health outbreaks, and any updates regarding our active watches (such as H5N1 in Australia, Tavneos, or other FDA/EMA decisions).

The search reveals a massive, explosive outbreak of *Cyclospora* (cyclosporiasis) in Michigan (over 700 cases) and other states, as well as an E. coli outbreak linked to frozen blueberries. Let's do some more searches to see if there are other major drug approvals, clinical trials, space/energy breakthroughs, or updates on our watches. Let's do a search on: - "Australia H5N1" - "Zvezda" or "ISS" leaks - "Tavneos" - "Genmab" or "AbbVie" - "Definium" - "Sobi" or "NASP" - "Omeros" or "narsoplimab" - "Replimune" or "RP1" - "Capricor" or "deramiocel" - "FDA approval" or "clinical trial" for other things. Let's run a search.

The bird flu situation in Australia is evolving: we have a seventh case (a giant petrel in Western Australia), but there is still no confirmed transmission to commercial poultry or local land wildlife/marine mammals (so the watch remains active and has not fired yet). Let's look for other drug approvals or clinical trials. Let's do a search for: - "FDA approval" or "FDA approved" in the last week - "Phase 3" results in the last week - "European Commission" or "EMA" approvals in the last week - "Zvezda" leak update - "Tavneos" update (is there any new news on Amgen's Tavneos?) Let's check.

Let's check the InflaRx development: "InflaRx seeks to fill void left by Amgen's Tavneos in Europe". That's a fascinating competitive update. I'll search for this specifically to see what InflaRx is doing. Let's fetch that page or do a search. Let's search for "InflaRx" and "Tavneos" or "Europe".

Let's fetch the article about InflaRx seeking to fill the void: `https://european-biotechnology.com/latest-news/inflarx-seeks-to-fill-void-left-by-amgens-tavneos-in-europe/` to get the specifics, quotes, and details. This will allow us to update the `amgen-tavneos-eu-revocation-us-fda-extension` slug or related slugs. Let's fetch it.

This is a perfect update for our Tavneos notes. The previous note `amgen-tavneos-eu-revocation-us-fda-extension` covers the CHMP recommendation to revoke Tavneos's marketing authorization and the NEJM retraction of the pivotal trial. We can update this note to include InflaRx's moves to fill the void, positioning its anti-C5a antibody vilobelimab (Gohibic) and C5aR inhibitor izicopan as upcoming alternatives in Europe. Let's do some more searches to see if there are other major science or health breakthroughs in the last 7 days. Let's search for: - "FDA approves" or "FDA approved" in the last week. Let's do a search on recent FDA actions.

Let's broaden the search to look for other drug approvals or clinical trial readouts from the past week. Let's search for "FDA approves" or "FDA approved" or "Phase 3" globally.

This is a major new drug approval. Today, July 7, 2026, the FDA approved Vera Therapeutics' **Trutakna (atacicept-vymj)** under the accelerated approval pathway to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk of disease progression. This is the first dual inhibitor treatment (targeting both BAFF and APRIL) for IgAN. Let's search for more details on this approval to write a high-quality finding. Let's do a search for "Vera Therapeutics" "atacicept" "Trutakna" "FDA" "July 2026" or "ORIGIN".

Let's fetch the GlobeNewswire release and the FiercePharma article to get precise details. First, let's fetch: `https://www.globenewswire.com/news-release/2026/07/07/3323532/0/en/vera-therapeutics-receives-fda-accelerated-approval-for-trutakna-for-adult-patients-with-primary-iga-nephropathy.html` (the official press release from Vera Therapeutics) or the STAT/FiercePharma article. Let's fetch the GlobeNewswire press release first. If that doesn't load, we can try Biospace or FiercePharma. Let's try GlobeNewswire.

This is extremely solid and provides exact quotes. Now we have two excellent stories: 1. Under slug `amgen-tavneos-eu-revocation-us-fda-extension` we will update the Tavneos story to include the competitive response from InflaRx, which is preparing to fill the market void left by Tavneos in Europe with its anti-C5a antibody vilobelimab (Phase 3 ready in AAV) and izicopan (Phase 2 planned). 2. A new finding for Vera Therapeutics' FDA accelerated approval of **Trutakna (atacicept-vymj)**. We can use the slug `vera-therapeutics-trutakna-fda-accelerated-approval-igan`. This is a major breakthrough in IgA nephropathy, being the first dual BAFF and APRIL inhibitor. Let's check if there are other updates on our watches. For example, let's search for: - "Capricor" "deramiocel" or "DMD" - "Replimune" "RP1" or "melanoma" - "MoonLake" "IZAR-1" or "sonelokimab" or "psoriatic arthritis" Let's see if there are any updates.

No new updates on the other watches (Capricor/Replimune/MoonLake's PsA trial) yet. The MoonLake news is still discussing the June 52-week VELA data in HS, and the PsA trial (IZAR-1) readout is still expected mid-2026 (so we keep watching). Let's do a search on the massive *Cyclospora* outbreak in Michigan to see if there's any public health action or identified food source. Let's do a search on "Cyclospora" or "cyclosporiasis" "Michigan" or "multistate" "CDC".

Let's fetch the Ars Technica article on the Cyclospora outbreak to get some excellent quotes and details on the science/epidemiology of it: `https://arstechnica.com/health/2026/07/michigan-sees-explosive-outbreak-of-diarrheal-parasite-with-over-700-cases/` Let's fetch it.

This is an incredible, highly detailed, and current primary source for the *Cyclospora* outbreak. We can write a dedicated finding for this using a stable slug like `cyclosporiasis-michigan-multistate-outbreak-2026`. Let's check if there are any other updates. Let's do a search on "E. coli" "blueberries" "July 2026" or "CDC" to see what that outbreak is about.

This is a second highly relevant public health outbreak story: GreenWise Organic frozen blueberries sold at Publix (recalled by Frutas y Hortalizas del Sur S.A., imported from Chile) linked to a multi-state E. coli O145:H28 outbreak. We can write a note under the slug `e-coli-frozen-blueberries-publix-multistate-outbreak-2026`. Let's fetch `https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/frutas-y-hortalizas-del-sur-sa-initiates-recall-frozen-greenwise-organic-iqf-blueberries-due` to get the primary details for our sources.

This is an excellent primary source with precise details. Let's review our findings plan: 1. Update `amgen-tavneos-eu-revocation-us-fda-extension`: We will update this note to include the June 29th NEJM retraction of the ADVOCATE study, the CHMP recommendation to revoke Tavneos's EU authorization on June 26th, and the news that InflaRx is actively positioning its anti-C5a antibody vilobelimab (Gohibic) and C5aR inhibitor izicopan to fill the market void left by Tavneos in Europe. 2. Write a new note `vera-therapeutics-trutakna-fda-accelerated-approval-igan`: Detail the FDA accelerated approval on July 7, 2026, of Vera Therapeutics' Trutakna (atacicept-vymj), the first dual BAFF and APRIL inhibitor for reducing proteinuria in primary IgA nephropathy, based on the Phase 3 ORIGIN 3 trial. 3. Write a new note `cyclosporiasis-michigan-multistate-outbreak-2026`: Detail the explosive outbreak of Cyclospora cayetanensis in Michigan with over 700 cases since June 22, 2026, and 36 hospitalizations, as well as the national surveillance context. 4. Write a new note `e-coli-frozen-blueberries-publix-multistate-outbreak-2026`: Detail the FDA and CDC investigation of a multi-state E. coli O145:H28 outbreak linked to recalled GreenWise Organic frozen blueberries sold at Publix stores across 8 states, imported from Chile by Frutas y Hortalizas del Sur S.A. Let's double-check if we need to update any other existing notes. Wait, let's look at the prior notes list: - `amgen-tavneos-eu-revocation-us-fda-extension` (updated on 2026-07-07) - `amgen-tavneos-fda-hearing-nejm-retraction` (updated on 2026-07-07) - `nejm-retracts-tavneos-advocate-trial-paper-amgen-fda-ema-withdrawal` (updated on 2026-07-07) Since we have multiple notes on Tavneos, let's reuse `amgen-tavneos-eu-revocation-us-fda-extension` as the single living document for this specific EU/US regulatory standoff and the competitive landscape update. Let's see if we can update it. Let's draft and write the notes now. I will construct the markdown body exactly as required: - No YAML frontmatter. - The title is the first `# ` heading. - Grounded in concrete evidence: actual names, links, and 1-2 representative verbatim quotes with their links. - No hand-built internal links; use `[[slug]]` syntax if linking to other findings. Let's write the first note. We'll update the existing Tavneos note: `amgen-tavneos-eu-revocation-us-fda-extension`. Let's fetch the existing note content first to see what was in it, or we can just overwrite it with an updated comprehensive view. Let's write the note.

Now let's write the second note for the FDA accelerated approval of Vera Therapeutics' **Trutakna (atacicept-vymj)**. We will use the slug `vera-therapeutics-trutakna-fda-accelerated-approval-igan`. Let's write it.

Now let's write the third note for the *Cyclospora* outbreak in Michigan: `cyclosporiasis-michigan-multistate-outbreak-2026`. Let's write it.

Now let's write the fourth note for the Publix frozen blueberries E. coli outbreak: `e-coli-frozen-blueberries-publix-multistate-outbreak-2026`. Let's write it.

Now let's see if there are any other threads or watches we should record. Wait, let's look at the watch list. We have a watch for "Amgen Tavneos FDA hearing submission extended deadline" with a fire date of July 29, 2026. This is still active. We also have a watch for "MoonLake Phase 3 IZAR-1 trial readout of sonelokimab in psoriatic arthritis" with a fire date of August 31, 2026. This is still active. We have a watch for "FDA traditional approval decision on Novartis's Vanrafia (atrasentan) in IgAN". Wait! Today, Vera Therapeutics' Trutakna (atacicept-vymj) got accelerated approval for IgA Nephropathy. And the press release states: "Continued approval for this indication may be contingent upon verification and description of clinical benefit in the ongoing ORIGIN 3 trial, which continues in a placebo-controlled, blinded manner to evaluate change in kidney function as measured by estimated glomerular filtration rate (eGFR), with results anticipated in Q3 2026." So we should register a new watch for the **Vera Therapeutics ORIGIN 3 trial eGFR confirmatory results (expected Q3 2026)**. Let's register this watch using `record_watch`. Let's do that.

This is registered beautifully. Let's see if there are other threads to resolve or record. There are no other immediate threads to resolve, as none of the active watches have fully resolved or fired yet (Australia H5N1 is still restricted to wild seabirds and has not reached poultry/wildlife/mammals, and other dates have not been reached). I am ready to call `finish_cycle`. Let's do that.

I have successfully completed the research cycle for this topic. Here is a summary of the findings: 1. **Amgen's Tavneos EU Revocation & Competitive Response (`amgen-tavneos-eu-revocation-us-fda-extension`)**: Updated the ongoing Tavneos regulatory crisis with the June 29, 2026, NEJM retraction of the ADVOCATE study and the June 26, 2026, CHMP recommendation to revoke EU marketing authorization. Significantly, competitor **InflaRx** is moving to fill this market void in Europe, positioning its Phase 3-ready anti-C5a monoclonal antibody **vilobelimab (Gohibic)** and oral C5aR inhibitor **izicopan** as upcoming alternatives. 2. **Trutakna FDA Accelerated Approval (`vera-therapeutics-trutakna-fda-accelerated-approval-igan`)**: Recorded the FDA's accelerated approval of Vera Therapeutics' **Trutakna (atacicept-vymj)** on July 7, 2026. It is the first dual BAFF and APRIL inhibitor approved to reduce proteinuria in primary IgA nephropathy. The approval is backed by a 46% baseline proteinuria reduction in the ORIGIN 3 trial, with confirmatory eGFR results expected in Q3 2026. 3. **Michigan Cyclosporiasis Outbreak (`cyclosporiasis-michigan-multistate-outbreak-2026`)**: Documented an explosive, unprecedented outbreak of the diarrheal parasite *Cyclospora cayetanensis* in Michigan, with over 700 cases and 36 hospitalizations reported since June 22. No specific food or produce source has yet been identified. 4. **Publix Blueberries E. coli Outbreak (`e-coli-frozen-blueberries-publix-multistate-outbreak-2026`)**: Documented a multi-state *E. coli* O145:H28 outbreak linked to recalled GreenWise Organic frozen blueberries sold at Publix supermarkets across eight states, which has hospitalized at least four individuals. Additionally, registered a new watch for the upcoming **Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory trial results** (expected Q3 2026) to track whether the drug successfully verifies its long-term clinical benefit.